{
    "clinical_study": {
        "@rank": "50270", 
        "arm_group": [
            {
                "arm_group_label": "Ischemic stroke", 
                "description": "Patients with an ischemic stroke admitted within 6 hours of symptom onset, with a minimum severity in the NIHSS of 3 and treated with systemic or intraarterial thrombolysis"
            }, 
            {
                "arm_group_label": "Healthy subjects", 
                "description": "Age-matched individuals free of acute neurological injury"
            }
        ], 
        "biospec_descr": {
            "textblock": "Whole blood, serum and plasma."
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Stroke is accompanied by local inflammatory response and systemic immunosuppression.\n      Immunosuppression markers are associated with the occurrence of medical complications\n      (infections), whereas inflammatory markers are associated with worse functional prognosis.\n\n      This prospective study tries to validate in acute stroke patients the prognostic usefulness\n      of a panel of immune biomarkers that have previously been associated with various clinical\n      outcomes.\n\n      The identification of beneficial and harmful immune responses in cerebral ischemia will\n      allow the prediction of the clinical course of the patients and will be helpful in designing\n      immunomodulatory therapeutic strategies for acute stroke."
        }, 
        "brief_title": "Immunological Biomarkers in Patients With Acute Ischemic Stroke", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Ischemic Stroke", 
        "condition_browse": {
            "mesh_term": [
                "Ischemia", 
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "Stroke is accompanied by local inflammatory response and systemic immunosuppression.\n      Immunosuppression markers are associated with the occurrence of medical complications\n      (infections), whereas inflammatory markers are associated with worse functional prognosis.\n\n      This prospective study tries to validate in acute stroke patients the prognostic usefulness\n      of a panel of immune biomarkers that have previously been associated with various clinical\n      outcomes. The immune biomarkers will be assessed at admission, at day 1 after admission and\n      at day 90. The assessed immune biomarker panel includes:\n\n        -  Serum cortisol levels.\n\n        -  Serum interleukin (IL)-10 levels.\n\n        -  Proportion of circulating B lymphocytes (CD3-CD19+ cells).\n\n        -  Monocyte surface expression of TLR4, HLA-DR, CD86, and VLA-4.\n\n        -  Ex - vivo production of tumor necrosis factor (TNF)-\u03b1 in monocytes after stimulation\n           with LPS.\n\n        -  Proportion of each of the circulating monocyte subpopulations (CD14highCD16-,\n           CD14highCD16+, and CD14dimCD16+).\n\n      The identification of beneficial and harmful immune responses in cerebral ischemia will\n      allow the prediction of the clinical course of the patients and will be helpful in designing\n      immunomodulatory therapeutic strategies for acute stroke."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  ischemic stroke*\n\n          -  stroke onset within 6h*\n\n          -  treated with systemic or intraarterial thrombolysis*\n\n          -  minimum severity in the NIHSS of 3*\n\n          -  age \u2265 18\n\n          -  consent by the patient or the legal representative\n\n               -  These items do not apply for healthy subjects.\n\n        Exclusion Criteria:\n\n          -  intracranial hemorrhage\n\n          -  signs of infection at admission\n\n          -  use of antibiotics, immunosuppressors or corticosteroids in the previous 3 months\n\n          -  significant disability (mRS>2) before index stroke"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with an ischemic stroke admitted within 6 hours of symptom onset, with a minimum\n        severity in the NIHSS of 3 and treated with systemic or intraarterial thrombolysis and\n        age-matched subjects free of acute neurological injury."
            }
        }, 
        "enrollment": {
            "#text": "125", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01894529", 
            "org_study_id": "PI09/1313"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ischemic stroke", 
            "immune biomarkers", 
            "stroke-associated infection", 
            "functional outcome", 
            "prediction"
        ], 
        "lastchanged_date": "July 4, 2013", 
        "link": {
            "description": "Home page of the Functional Unit of Cerebrovascular Diseases, Hospital Clinic of Barcelona", 
            "url": "http://www.ictusclinic.com/home.aspx"
        }, 
        "location": {
            "contact": {
                "email": "achamorro@clinic.ub.es", 
                "last_name": "Angel Chamorro, MD, PhD", 
                "phone": "0034 93 227 54 14"
            }, 
            "contact_backup": {
                "email": "xurra@clinic.ub.es", 
                "last_name": "Xabier Urra, MD, PhD", 
                "phone": "0034 93 227 2118"
            }, 
            "facility": {
                "address": {
                    "city": "Barcelona", 
                    "country": "Spain", 
                    "zip": "08036"
                }, 
                "name": "Functional Unit of Cerebrovascular Diseases, Hospital Cl\u00ednic of Barcelona"
            }, 
            "investigator": [
                {
                    "last_name": "Xabier Urra, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "V\u00edctor Obach, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Luis San Rom\u00e1n, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Martha Vargas, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Francisca Ruiz", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_groups": "2", 
        "official_title": "Clinical Implications of a Panel of Immunological Biomarkers in Patients With Acute Ischemic Stroke", 
        "overall_contact": {
            "email": "achamorro@clinic.ub.es", 
            "last_name": "Angel Chamorro, MD, PhD", 
            "phone": "0034 93 227 5414"
        }, 
        "overall_contact_backup": {
            "email": "xurra@clinic.ub.es", 
            "last_name": "Xabier Urra, MD, PhD", 
            "phone": "0034 93 227 2118"
        }, 
        "overall_official": {
            "affiliation": "Functional Unit of Cerebrovascular Diseases (Hospital Cl\u00ednic of Barcelona), IDIBAPS and University of Barcelona Barcelona, Spain", 
            "last_name": "Angel Chamorro, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To establish a predictive immune score for functional outcome. Favorable outcome is defined as a modified Rankin Scale (mRS) score of <3 at day 90+-15 after stroke", 
                "measure": "Predictive immune score for favorable outcome", 
                "safety_issue": "No", 
                "time_frame": "90 +-15 days after onset of symptoms"
            }, 
            {
                "description": "To establish a predictive score for stroke associated infection (SAI) based on immune biomarkers. Stroke associated infection is defined as: body temperature > 37.7\u00baC and symptoms of infection (cough, dyspnea, pleuritic pain, dysuria), or leukocytosis >11000, leukopenia <4000, pulmonary infiltrates in chest X-ray or positive cultures for a pathogen.", 
                "measure": "Predictive immune score for stroke associated infection", 
                "safety_issue": "No", 
                "time_frame": "7 days after onset of symptoms"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01894529"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital Clinic of Barcelona", 
            "investigator_full_name": "Angel Chamorro, M.D., Ph.D.", 
            "investigator_title": "\u00c1ngel Chamorro", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To establish a predictive score for ischemic progression based in a panel of immune biomarkers. Ischemic progression is defined as an increase of \u22654 points in the National Institutes of Health Stroke Scale(NIHSS) score in the absence of bleeding in the CT scan.", 
                "measure": "Predictive immune score for ischemic progression", 
                "safety_issue": "No", 
                "time_frame": "7 days after onset of symptoms"
            }, 
            {
                "description": "To establish a predictive score for functional outcome based in a panel of immune biomarkers and using shift analysis of the entire mRS", 
                "measure": "Predictive immune score for functional outcome over the entire mRS", 
                "safety_issue": "No", 
                "time_frame": "90 +-15 days after onset of symptoms"
            }, 
            {
                "description": "To investigate the influence of the localization and stroke volume on the occurrence of a stroke associated infection and on neurological outcome", 
                "measure": "Localization and stroke volume analysis", 
                "safety_issue": "No", 
                "time_frame": "SAI within 7 days and neurological outcome after 3 months after onset of symptoms"
            }, 
            {
                "description": "To investigate the influence of insular cortex involvement and infarct volume on the occurrence of a SAI and on the neurological outcome after 3 months", 
                "measure": "Insular cortex involvement and infarct volume", 
                "safety_issue": "No", 
                "time_frame": "SAI within 7 days and and on the neurological outcome after 3 months"
            }, 
            {
                "description": "To assess the independent effect of SAI over the functional outcome at 3 months", 
                "measure": "Infection and functional outcome after ischemic stroke", 
                "safety_issue": "No", 
                "time_frame": "SAI within 7 days after onset of symptoms and neurological outcome after 3 months"
            }, 
            {
                "description": "To assess the effect of thrombolytic treatment over changes in the immune biomarker panel and over the occurrence of SAI", 
                "measure": "Thrombolysis, immune biomarkers and SAI", 
                "safety_issue": "No", 
                "time_frame": "SAI within 7 days after onset of symptoms"
            }
        ], 
        "source": "Hospital Clinic of Barcelona", 
        "sponsors": {
            "collaborator": {
                "agency": "Instituto de Salud Carlos III", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Hospital Clinic of Barcelona", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2010", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "July 2013"
    }
}